Laser and eye drop combo may offer new hope for baby tumors
NCT ID NCT07560332
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compared two treatments for infantile hemangioma, a common benign tumor in children. One group received oral propranolol daily for 3 months, while the other had weekly fractional CO2 laser sessions followed by topical timolol drops. The trial enrolled 30 children aged 1 month to 12 years and measured improvement using a global assessment score. The goal was to see if the laser-and-drop approach works as well as the oral medication.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- propranolol (oral) and timolol (topical)
- What this could lead to
- If successful, this could show that laser-assisted topical timolol is as effective as oral propranolol, offering a less invasive treatment option for infantile hemangioma.
- What could go wrong
- This is a small, completed trial with only 30 participants, so results may not apply broadly. Both treatments have known side effects, and the laser procedure may cause discomfort or scarring.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
30 people
The number who actually took part.
- Started
-
Jan 2025
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 month to 12 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: , aged 1 month to 12 years \- presenting with superficial, deep, mixed, or proliferating IH. Exclusion Criteria: * other cutaneous or systemic infections * chronic systemic diseases * known allergy to topical timolol maleate * contraindications to laser or beta-blocker therapy * IH involving mucosal or perimucosal sites * and a history of adverse reactions to laser therapy or keloid tendency.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Infantile hemangioma (IH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cairo University
Cairo, 11562, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.